実績紹介



2021年度の実績はResearch Report 2021をご覧ください。

  • がんワクチン部門
  • 肝癌部門
  • 分子標的部門
2020
1
Shimose S, Kawaguchi T, Iwamoto H, Tanaka M, Miyazaki K, Ono M, Niizeki T, Shirono T, Okamura S, Nakano M, Suga H, Yamaguchi T, Yokokura Y, Noguchi K, Koga H, Torimura T. Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study. Nutrients. 2020 Apr 13; 12(4): 1076.
2
Iwamoto H, Suzuki H, Shimose S, Niizeki T, Nakano M, Shirono T, Okamura S, Noda Y, Kamachi N, Nakamura T, Masuda A, Sakaue T, Tanaka T, Nakano D, Sakai M, Yamaguchi T, Kuromatsu R, Koga H, Torimura T. Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability toward Adverse Events. Cancers (Basel). 2020 Apr 19; 12(4): 1010.
3
Nakano D, Kawaguchi T, Iwamoto H, Hayakawa M, Koga H, Torimura T. Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT). PLoS One. 2020 Apr 28; 15(4): e0232283.
4
Shimose S, Kawaguchi T, Iwamoto H, Niizeki T, Shirono T, Tanaka M, Koga H, Torimura T. Indication of suitable transarterial chemoembolization and multikinase inhibitors for intermediate stage hepatocellular carcinoma. Oncol Lett. 2020 Apr; 19(4): 2667-2676.
5
Nakaji S, Okawa Y, Nakamura K, Itonaga M, Inase M, Sugiyama H, Suzuki R, Yamauchi K, Matsui H, Hirata N, Saito J, Ishii N, Tsuyuguchi T, Kato H, Kitano M, Kato N, Ohira H, Okada H, Torimura T, Maguchi H. Predictive model of bleeding following endoscopic sphincterotomy for the treatment of choledocholithiasis in hemodialysis patients: A retrospective multicenter study. JGH Open. 2020 May 17; 4(5): 915-922.
6
Nakano M, Kuromatsu R, Niizeki T, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Kamachi N, Koga H, Torimura T; Kurume Liver Cancer Study Group of Japan. Primary Treatment with Molecular-Targeted Agents for Hepatocellular Carcinoma: A Propensity Score-matching Analysis. Hepatol Commun. 2020 Jun 20; 4(8): 1218-1228.
7
Watanabe Y, Numakura C, Tahara T, Fukui K, Torimura T, Hiromatsu Y, Tomotsune K, Yamakawa M, Hayasaka K. Diabetes mellitus exacerbates citrin deficiency via glucose toxicity. Diabetes Res Clin Pract. 2020 Jun; 164: 108159.
8
Shigeto K, Kawaguchi T, Koya S, Hirota K, Tanaka T, Nagasu S, Fukahori M, Ushijima T, Matsuse H, Miwa K, Nagafuji K, Torimura T. Profiles Combining Muscle Atrophy and Neutrophil-to-Lymphocyte Ratio Are Associated with Prognosis of Patients with Stage IV Gastric Cancer. Nutrients. 2020 Jun 24; 12(6): 1884.
9
Ito S, Tahara N, Hirakata S, Kaieda S, Tahara A, Maeda-Ogata S, Bekki M, Sugiyama Y, Honda A, Igata S, Kuromatsu R, Nakashima O, Fukumoto Y. Signal intensity of superb micro-vascular imaging associates with the activity of vascular inflammation in Takayasu arteritis. J Nucl Cardiol. 2020 Jun; 27(3): 1063-1065.
10
Masuda A, Nakamura T, Abe M, Iwamoto H, Sakaue T, Tanaka T, Suzuki H, Koga H, Torimura T. Promotion of liver regeneration and anti fibrotic effects of the TGF β receptor kinase inhibitor galunisertib in CCl4 treated mice. Int J Mol Med. 2020 Jul; 46(1): 427-438.
11
Shimose S, Iwamoto H, Niizeki T, Shirono T, Noda Y, Kamachi N, Okamura S, Nakano M, Suga H, Kuromatsu R, Yamaguchi T, Kawaguchi T, Tanaka M, Noguchi K, Koga H, Torimura T. Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study. Cancers (Basel). 2020 Jul 11; 12(7): 1867.
12
Shioga T, Kondo R, Ogasawara S, Akiba J, Mizuochi S, Kusano H, Mihara Y, Tanigawa M, Kinjyo Y, Naito Y, Kuromatsu R, Nakashima O, Yano H. Usefulness of Tumor Tissue Biopsy for Predicting the Biological Behavior of Hepatocellular Carcinoma. Anticancer Res. 2020 Jul; 40(7): 4105-4113.
13
Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Yasui K, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Yokosuka O, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson PJ, Arai Y; TACTICS study group. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2020 Aug; 69(8): 1492-1501.
14
Takahashi A, Ohira H, Abe K, Zeniya M, Abe M, Arinaga-Hino T, Torimura T, Yoshizawa K, Takaki A, Kang JH, Suzuki Y, Nakamoto N, Inui A, Tanaka A, Takikawa H. Increasing incidence of acute autoimmune hepatitis: a nationwide survey in Japan. Sci Rep. 2020 Aug 28; 10(1): 14250.
15
Shimose S, Kawaguchi T, Tanaka M, Iwamoto H, Miyazaki K, Moriyama E, Suzuki H, Niizeki T, Shirono T, Nakano M, Suga H, Yamaguchi T, Yokokura Y, Noguchi K, Koga H, Torimura T. Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis. Oncol Lett. 2020 Sep; 20(3): 2257-2265.
16
Iwanaga S, Hashida R, Takano Y, Bekki M, Nakano D, Omoto M, Nago T, Kawaguchi T, Matsuse H, Torimura T, Shiba N. Hybrid Training System Improves Insulin Resistance in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Pilot Study. Tohoku J Exp Med. 2020 Sep; 252(1): 23-32.
17
Kudo M, Kurosaki M, Ikeda M, Aikata H, Hiraoka A, Torimura T, Sakamoto N. Treatment of hepatocellular carcinoma during the COVID-19 outbreak: The Working Group report of JAMTT-HCC. Hepatol Res. 2020 Sep; 50(9): 1004-1014.
18
Kawaguchi T, Shimose S, Yamamura S, Nakano D, Tanaka M, Torimura T. Changes in prognostic factors for patients with hepatocellular carcinoma underwent transarterial chemoembolization with the transition of the time: Child-Pugh class, Albumin-Bilirubin grade, and then. Ann Transl Med. 2020 Sep; 8(17): 1045.
19
Seki T, Hosaka K, Fischer C, Lim S, Andersson P, Abe M, Iwamoto H, Gao Y, Wang X, Fong GH, Cao Y. Correction: Ablation of endothelial VEGFR1 improves metabolic dysfunction by inducing adipose tissue browning. J Exp Med. 2020 Sep 7; 217(9): jem.2017101208112020c.
20
Takahashi A, Abe M, Yasunaka T, Arinaga-Hino T, Abe K, Takaki A, Torimura T, Zeniya M, Yoshizawea K, Kang JH, Suzuki Y, Nakamoto N, Inui A, Tanaka A, Takikawa H, Ohira H. Quality of life among patients with autoimmune hepatitis in remission: A comparative study. Medicine (Baltimore). 2020 Oct 23; 99(43): e22764.
21
Shimose S, Iwamoto H, Tanaka M, Niizeki T, Shirono T, Nakano M, Okamura S, Noda Y, Kamachi N, Sakai M, Suzuki H, Nomiyama M, Kuromatsu R, Koga H, Torimura T. Increased Arterio-Portal Shunt Formation after Drug-Eluting Beads TACE for Hepatocellular Carcinoma. Oncology. 2020; 98(8): 558-565.
22
Yamamura S, Eslam M, Kawaguchi T, Tsutsumi T, Nakano D, Yoshinaga S, Takahashi H, Anzai K, George J, Torimura T. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int. 2020 Dec; 40(12): 3018-3030.
23
Narao H, Hirota K, Koya S, Tomita M, Manako Y, Ogawa S, Nakao N, Tsutsumi T, Nakano D, Hashida R, Kawaguchi T, Matsuse H, Nagamatu H, Torimura T. Effects of In-Hospital Physical Therapy on Activities of Daily Living in Patients with Hepatocellular Carcinoma. Int J Environ Res Public Health. 2020 Dec 6; 17(23): 9098.
24
Takahashi H, Nakahara T, Kogiso T, Imajo K, Kessoku T, Kawaguchi T, Ide T, Kawanaka M, Hyogo H, Fujii H, Ono M, Kamada Y, Sumida Y, Anzai K, Shimizu M, Torimura T, Nakajima A, Tokushige K, Chayama K, Eguchi Y, Japan Study Group of NAFLD (JSG-NAFLD). Eradication of hepatitis C virus with direct-acting antivirals improves glycemic control in diabetes: A multicenter study. JGH Open. 2020 Dec 19; 5(2): 228-234.
25
Yasumoto M, Araki T, Okabe Y, Niizeki T, Shirono T, Ishida Y, Ushijima T, Sakaue T, Tsuruta O, Torimura T. Nihon Shokakibyo Gakkai Zasshi. [A case of hemobilia due to the rupture of pancreaticoduodenal artery aneurysm with choledocholithiasis]. 2020; 117(1): 92-98.
26
Nakano D, Kawaguchi T, Tsutusumi T, Yamamura S, Shigeto K, Hashida R, Koga H, Torimura T. Alteration of the serum myostatin level following L carnitine treatment in patients with chronic liver disease: A pilot study. Int J Funct Nutr. 2020; 1(1): 1-7.
27
Sato F, Ono T, Kawahara A, Matsuo K, Kondo R, Sato K, Akiba J, Kawaguchi T, Kakuma T, Chitose SI, Umeno H, Yano H. Prognostic Value of Tumor Proportion Score in Salivary Gland Carcinoma. Laryngoscope. 2020.
28
Renne SL, Woo HY, Allegra S, Rudini N, Yano H, Donadon M, Vigano L, Akiba J, Lee HS, Rhee H, Park YN, Roncalli M, Di Tommaso L. Vessels Encapsulating Tumor Clusters (VETC) Is a Powerful Predictor of Aggressive Hepatocellular Carcinoma. Hepatology. 2020; 71(1): 183-195.
29
Kusano H, Naito Y, Mihara Y, Kondo R, Ogasawara S, Akiba J, Nakashima O, Yano H. Distinctive clinicopathological features and KRAS and IDH1/2 mutation status of cholangiolocellular carcinoma. Hepatol Res. 2020; 50(1): 84-91.
30
Kurose H, Ueda K, Uegaki M, Ogasawara N, Kumagae H, Chikui K, Nakiri M, Nishihara K, Matsuo M, Suekane S, Akiba J, Yano H, Igawa T. Paraganglioma of the urinary bladder: Case report and literature review. IJU Case Rep. 2020; 3(5): 192-195.
31
Kojima S, Hisaka T, Midorikawa R, Naito Y, Akiba J, Tanigawa M, Yano H, Akagi Y, Okuda K. Prognostic Impact of Desmoplastic Reaction Evaluation for Intrahepatic Cholangiocarcinoma. Anticancer Res. 2020; 40(8): 4749-4754.
32
Kage M, Aishima S, Kusano H, Yano H. Histopathological findings of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Med Ultrason (2001). 2020; 47(4): 549-554.
33
Hisaka T, Sakai H, Sato T, Goto Y, Nomura Y, Fukutomi S, Fujita F, Mizobe T, Nakashima O, Tanigawa M, Naito Y, Akiba J, Ogasawara S, Nakashima K, Akagi Y, Okuda K, Yano H. Quercetin Suppresses Proliferation of Liver Cancer Cell Lines In Vitro. Anticancer Res. 2020; 40(8): 4695-4700.
34
Akiba J, Fujita N, Yano H. Recent Topics Concerning Combined Hepatocellular Cholangiocarcinoma. Kurume Med J. 2020; 66(1): 29-36.
35
Akashi M, Yamaguchi R, Kusano H, Ogasawara S, Abe E, Obara H, Yamaguchi M, Akiba J, Kakuma T, Tanaka M, Akagi Y, Yano H. Androgen receptor expression is useful to predict the therapeutic effect in HER2-positive breast carcinoma. Breast Cancer Res Treat. 2020; 184(2): 277-285.
36
Akashi M, Yamaguchi R, Kusano H, Obara H, Yamaguchi M, Toh U, Akiba J, Kakuma T, Tanaka M, Akagi Y, Yano H. Diverse histomorphology of HER2-positive breast carcinomas based on differential ER expression. Histopathology. 2020; 76(4): 560-571.
37
Hashida R, Takano Y, Matsuse H, Kudo M, Bekki M, Omoto M, Nago T, Kawaguchi T, Torimura T, Shiba N. Electrical Stimulation of the Antagonist Muscle during Cycling Exercise Interval Training Improves Oxygen Uptake and Muscle Strength. J Strength Cond Res. 2021 Jan 1; 35(1): 111-117.
38
Shimose S, Iwamoto H, Tanaka M, Niizeki T, Shirono T, Noda Y, Kamachi N, Okamura S, Nakano M, Suga H, Yamaguchi T, Kawaguchi T, Kuromatsu R, Noguchi K, Koga H, Torimura T. Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study. Cancers(Basel). 2021 Jan 5; 13(1): 160.
39
Sano T, Amano K, Ide T, Kawaguchi T, Kuwahara R, Arinaga-Hino T, Koga H, Kuromatsu R, Torimura T. Short-term efficacy after switching from adefovir dipivoxil and tenofovir disoproxil fumarate therapy to tenofovir alaferamide for chronic hepatitis B. Biomed Rep. 2021 Jan; 14(1): 12.
40
Tsuchihashi J, Koya S, Hirota K, Koga N, Narao H, Tomita M, Kawaguchi T, Hashida R, Nakano D, Tsutsumi T, Yoshio S, Matsuse H, Sanada T, Notsumata K, Torimura T. Effects of In-Hospital Exercise on Frailty in Patients with Hepatocellular Carcinoma. Cancers(Basel). 2021 Jan 7; 13(2): E194.
41
Murayama K, Okada M, Tanaka K, Inadomi C, Yoshioka W, Kubotsu Y, Yada T, Isoda H, Kuwashiro T, Oeda S, Akiyama T, Oza N, Hyogo H, Ono M, Kawaguchi T, Torimura T, Anzai K, Eguchi Y, Takahashi H. Prediction of Nonalcoholic Fatty Liver Disease Using Noninvasive and Non-Imaging Procedures in Japanese Health Checkup Examinees. Diagnostics(Basel). 2021 Jan 16; 11(1): 132.
42
Kawaguchi A, Akiba J, Kondo R, Sadashima E, Ogasawara S, Naito Y, Kusano H, Sanada S, Muto I, Nakama T, Yano H. Programmed Death-Ligand 1 and Programmed Death-Ligand 2 Expression Can Affect Prognosis in Extramammary Paget’s Disease. Anticancer Res. 2021 Jan; 41(1): 219-226.
43
Kawaguchi T, Arinaga-Hino T, Morishige S, Mizuochi S, Abe M, Kunitake K, Sano T, Amano K, Kuwahara R, Ide T, Nagafuji K, Torimura T. Prednisolone-responsive primary sclerosing cholangitis with autoimmune hemolytic anemia: a case report and review of the literature. Clin J Gastroenterol. 2021 Feb; 14(1): 330-335.
44
Fukahori M, Kato K, Taniguchi H, Ohtomo R, Takahashi N, Shoji H, Iwasa S, Honma Y, Takashima A, Hamaguchi T, Yamada Y, Shimada Y, Ito Y, Itami J, Hokamura N, Igaki H, Tachimori Y, Miwa K, Torimura T, Boku N. Relationship between cervical esophageal squamous cell carcinoma and human papilloma virus infection and gene mutations. Mol Clin Oncol. 2021 Feb; 14(2): 41.
45
Iwamoto H, Niizeki T, Nagamatsu H, Ueshima K, Nomura T, Kuzuya T, Kasai K, Kooka Y, Hiraoka A, Sugimoto R, Yonezawa T, Ishihara A, Deguchi A, Arai H, Shimose S, Shirono T, Nakano M, Okamura S, Noda Y, Kamachi N, Sakai M, Suzuki H, Aino H, Matsukuma N, Matsugaki S, Ogata K, Yano Y, Ueno T, Kajiwara M, Itano S, Fukuizumi K, Kawano H, Noguchi K, Tanaka M, Yamaguchi T, Kuromatsu R, Kawaguchi A, Koga H, Torimura T. Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma. Cancers(Basel). 2021 Feb 5; 13(4): 646.
46
Nakano M, Kuromatsu R, Niizeki T, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Kamachi N, Koga H, Torimura T, Kurume Liver Cancer Study Group of Japan. Immunological inflammatory biomarkers as prognostic predictors for advanced hepatocellular carcinoma. ESMO Open. 2021 Feb; 6(1): 100020.
47
Shirono T, Niizeki T, Iwamoto H, Shimose S, Suzuki H, Kawaguchi T, Kamachi N, Noda Y, Okamura S, Nakano M, Kuromatu R, Koga H, Torimura T. Therapeutic Outcomes and Prognostic Factors of Unresectable Intrahepatic Cholangiocarcinoma: A Data Mining Analysis. J Clin Med. 2021 Mar 2; 10(5): 987.
48
Yamamura S, Nakano D, Hashida R, Tsutsumi T, Kawaguchi T, Okada M, Isoda H, Takahashi H, Matsuse H, Eguchi Y, Sumida Y, Nakajima A, Gerber L, Younossi ZM, Torimura T. Patient-reported outcomes in patients with non-alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 2021 Mar; 36(3): 629-636.
49
Takahashi A, Ohira H, Abe K, Zeniya M, Abe M, Arinaga-Hino T, Torimura T, Yoshizawa K, Takaki A, Kang JH, Suzuki Y, Nakamoto N, Inui A, Tanaka A, Takikawa H. Differences in autoimmune hepatitis based on inflammation localization. Med Mol Morphol. 2021 Mar; 54(1): 8-13.
50
Yano Y, Akiba J, Naito Y, Sadashima E, Cho H, Hishima T, Yano H. Sulfite Oxidase Is a Novel Prognostic Biomarker of Advanced Gastric Cancer. In Vivo. 2021; 35(1): 229-237.
51
Nomura Y, Sakai H, Akiba J, Hisaka T, Sato T, Goto Y, Akashi M, Fukutomi S, Muroya D, Kanno H, Okamura S, Yano Y, Yano H, Akagi Y, Okuda K. Laparoscopic left hepatectomy for a patient with intrahepatic cholangiocarcinoma metastasis in the falciform ligament: a case report. BMC Surg. 2021; 21(1): 122.
52
Kamachi N, Shimose S, Hirota K, Koya S, Iwamoto H, Niizeki T, Shirono T, Nakano M, Hashida R, Kawaguchi T, Matuse H, Noguchi K, Koga H, Torimura T. Prevalence and profiles of ramucirumab-associated severe ascites in patients with hepatocellular carcinoma. Mol Clin Oncol. 2021 Apr; 14(4): 79.
53
Nakano C, Nishimura T, Tada T, Yoshida M, Takashima T, Aizawa N, Ikeda N, Nishikawa H, Enomoto H, Hatano E, Yano H, Hirota S, Hachiya H, Iijima H. Severity of liver fibrosis using shear wave elastography is influenced by hepatic necroinflammation in chronic hepatitis patients, but not in cirrhotic patients. Hepatol Res. 2021 Apr; 51(4): 436-444.
54
Toshihiro Tanaka, Hideki Iwamoto, Mitsuteru Fujihara, Hideyuki Nishiofuku, Tetsuya Masada, Hiroyuki Suzuki, Hironori Koga, Takuji Torimura, Kimihiko Kichikawa. Efficacy of a Glass Membrane Emulsification Device to Form Mixture of Cisplatin Powder with Lipiodol on Transarterial Therapy for Hepatocellular Carcinoma. Cardiovasc Intervent Radio. 2021 May; 44(5): 766-773.
55
Akashi M, Yamaguchi R, Kusano H, Yamaguchi M, Akiba J, Kakuma T, Tanaka M, Akagi Y, Yano H. ER staining levels affect HER2 staining and heterogeneity. Breast Cancer. 2021 May; 28(3): 720-726.
56
Iwaki M, Kessoku T, Ozaki A, Kasai Y, Kobayashi T, Nogami A, Honda Y, Ogawa Y, Imajo K, Yoneda M, Maeda A, Tanaka Y, Nakajima S, Ohno H, Usuda H, Kawanaka M, Kawaguchi T, Torimura T, Kage M, Hyogo H, Takahashi H, Eguchi Y, Aishima S, Wada K, Kobayash N, Sumida Y, Saito S, Nakajima A. Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2021. inpress.
57
Casadei-Gardini A, Scartozzi M, Tada T, Yoo C, Shimose S, Masi G, Lonardi S, Frassineti GL, Nicola S, Piscaglia F, Kumada T, Hyung-Don K, Koga H, Vivaldi C, Sold C, Hiraoka A, Bang Y, Atsukawa M, Torimura T, Tsuj K, Itobayashi E, Toyoda H, Fukunishi S, Rimassa L, Rimini M, Cascinu S, Cucchetti A. Lenvatinib versus Sorafenib in first-line treatment of unresectable hepatocellular carcinoma: an inverse probability of treatment weighting analysis. Liver int. 2021. inpress.